Physician profile
Jeremy D Jackson
NPI 1790996544
$450,020.64
in general payments reported to CMS, 2019-2025
36 companies · $57K in 2025
The $57K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119K · 2020: $35K · 2021: $46K · 2022: $73K · 2023: $56K · 2024: $64K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Travel and Lodging: $12K · Consulting Fee: $7,163 · Food and Beverage: $5,741 · Education: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151,051.00 |
| Travel and Lodging | $11,583.93 |
| Consulting Fee | $7,162.50 |
| Food and Beverage | $5,741.40 |
| Education | $1,478.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $135,123.43 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $100,377.04 | 2019-2022 | |
| Janssen Biotech, INC. | $69,960.52 | 2019-2025 | Tremfya, Darzalex, Tecvayli |
| Genzyme Corporation | $48,960.95 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $36,208.35 | 2019-2025 | |
| Pfizer INC. | $14,900.43 | 2019-2025 | |
| Dusa Pharmaceuticals, INC. | $11,292.47 | 2019 | |
| Sun Pharmaceutical Industries INC. | $8,893.93 | 2019-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $6,879.82 | 2019-2022 | |
| Argenx US, INC. | $6,830.41 | 2023 | Vyvgart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,783.46 | 2020-2024 | Spevigo |
| Dermavant Sciences, INC. | $1,445.00 | 2024 | Vtama |
| Mallinckrodt Hospital Products INC. | $287.28 | 2023-2025 | Acthar, Uvadex |
| Galderma Laboratories, L.P. | $283.73 | 2025 | Nemluvio |
| Kyowa Kirin, INC. | $277.00 | 2019-2023 | Poteligeo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $207.76 | 2020-2025 | Bimzelx |
| Lilly USA, LLC | $203.22 | 2020-2025 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $197.68 | 2020-2025 | Dupixent |
| Leo Pharma INC. | $177.26 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $120.70 | 2022-2024 | Sotyktu |
| Organon LLC | $96.67 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.34 | 2021 | |
| Almirall LLC | $76.46 | 2019-2024 | Klisyri |
| Arcutis Biotherapeutics, INC. | $73.18 | 2024-2025 | Zoryve |
| Amgen INC. | $56.24 | 2025 | Otezla |
| Convatec INC. | $32.76 | 2025 | |
| Celgene Corporation | $29.95 | 2019 | |
| Incyte Corporation | $28.92 | 2022 | |
| Adc Therapeutics America, INC. | $22.18 | 2024 | |
| Seagen INC. | $20.59 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.56 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $16.13 | 2019 | |
| Dova Pharmaceuticals | $15.35 | 2021 | |
| Bausch Health US, LLC | $14.48 | 2021 | |
| Merck Sharp & Dohme LLC | $13.79 | 2024 | Welireg, Keytruda |
| Botanix Sb INC | $13.60 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.